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Background: Identification of the best management strategy for nodules with Thy3 cytology presents particular
problems for clinicians. This study investigates the ability of clinical, cytological and sonographic data to predict
malignancy in indeterminate nodules with the scope of determining the need for total thyroidectomy in these
patients.
Methods: The study population consisted of 249 cases presenting indeterminate nodules (Thy3): 198 females
(79.5%) and 51 males (20.5%) with a mean age of 52.43 ± 13.68 years. All patients underwent total thyroidectomy.
Results: Malignancy was diagnosed in 87/249 patients (34.9%); thyroiditis co-existed in 119/249 cases (47.79%) and
was associated with cancer in 40 cases (40/87; 45.98%). Of the sonographic characteristics, only echogenicity and
the presence of irregular margins were identified as being statistically significant predictors of malignancy. 52/162
benign lesions (32.1%) and 54/87 malignant were hypoechoic (62.07%); irregular margins were present in 13/162
benign lesions (8.02%), and in 60/87 malignant lesions (68.97%). None of the clinical or cytological features, on the
other hand, including age, gender, nodule size, the presence of microcalcifications or type 3 vascularization, were
significantly associated with malignancy.
Conclusions: The rate of malignancy in cytologically indeterminate lesions was high in the present study sample
compared to other reported rates, and in a significant number of cases Hashimoto’s thyroiditis was also detected.
Thus, considering the fact that clinical and cytological features were found to be inaccurate predictors of
malignancy, it is our opinion that surgery should always be recommended. Moreover, total thyroidectomy is
advisable, being the most suitable procedure in cases of multiple lesions, hyperplastic nodular goiter, or thyroiditis;
the high incidence of malignancy and the unreliability of intraoperative frozen section examination also support
this preference for total over hemi-thyroidectomy.
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Clinically palpable thyroid nodules are common and
can be found in 4-20% of the adult population [1-4].
Ultrasound-detectable nodules, however, may be pre-
sent in 30-50% of the population [3,5]. They are usually
benign [1,2,6-8]; however, 5-15% prove to be malig-
nant [1,2,4,5,7,9].
Fine needle aspiration cytology (FNAC) represents the
main diagnostic tool currently used in the evaluation of
thyroid nodules due to its high sensitivity, specificity,* Correspondence: pgcalo@unica.it
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unless otherwise stated.accuracy, reproducibility, and low cost [2-5,9-14]. A
number of classification systems are used in the eva-
luation of FNAC results. In the guidelines published in
2006 by the American Thyroid Association (ATA) and
the American Association of Clinical Endocrinologists
(AACE), cytological findings that are suspicious for
malignancy as well as follicular lesions and follicular
neoplasms (FN) were classified under the heading of
“indeterminate”. These guidelines were revised by ATA
in 2009, and the “indeterminate” classification was rede-
fined to differentiate between follicular and Hürthle cell
neoplasms and follicular lesions of undetermined sig-
nificance. Hürthle cell lesions have been described as ad. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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system [5]. In 2007, the ‘Thy’ classification system was
introduced by the British Thyroid Association (BTA) to
guide the management of the thyroid nodules based on
FNAC analysis of the thyroid. They suggested a manage-
ment plan for each of the five diagnostic categories ob-
tained (Thy1 to Thy5) [2].
Identification of the best management strategy for
nodules with Thy3 cytology, which accounts for 5-30% of
all patients with thyroid nodules [1,3,7,11,15], presents
particular problems for clinicians. Most patients with
cytologically indeterminate nodules are referred for thy-
roid surgery due to the fact that the presence of follicular
thyroid malignancy cannot be ruled out, even though the
majority are subsequently identified as having benign dis-
ease [1,3,12,16,17]. For these patients, thyroid surgery was
unnecessary, yet it exposed them to a 2-10% risk of serious
surgical complications, and patients are then required to
take levothyroxine replacement therapy for life [1,12]. In
the literature, the reported malignancy rate for indeter-
minate lesions (Thy3) varies between 3% and 52% of Thy3
cases [2,15,18-20].
Efforts have been made to identify criteria able to
predict malignancy in Thy3 nodules. Some studies have
identified the male gender, age, nodule size, shape, border
characteristics, hypoechogenicity, and the presence of mi-
crocalcifications as risk factors for malignancy in indeter-
minate follicular lesions [3,4,21], but other studies show
no evidence for this [14,22].
Here, we report the clinical, cytological (FNAC) and
sonographic data obtained from 249 patients diagnosed
with “follicular neoplasm” (Thy3) and correlate the data
with the malignancy rates determined post-thyroidectomy
with the scope of identifying risk factors of malignancy
and to determine whether total thyroidectomy was indeed
the best therapeutic option for these patients.
Methods
Thyroid FNACs performed in patients referred to the
Department of Surgery of the University of Cagliari (a
tertiary care referral endocrine surgical center) between
January 2009 and December 2012 were classified accor-
ding to the guidelines published by the British Thyroid
Association as: non diagnostic (Thy1), benign (Thy2),
indeterminate (Thy3), suspicious for malignancy (Thy4),
or malignant (Thy5). According to these evaluations,
249 cases with indeterminate nodules (Thy3) were in-
cluded in this retrospective study. Of these, 198 were
female (79.5%) and 51 male (20.5%), with a mean age of
52.43 ± 13.68 years. All patients with Thy3 nodules under-
went total thyroidectomy (TT), as routinely practiced in
this Institute; indeed intraoperative frozen section exami-
nation was not used as a means of diagnosing thyroid can-
cer and to determine the extent of thyroidectomy sinceour pathologists consider the usefulness of this proce-
dure to be very limited with little benefit in terms of pa-
tient outcome. Age, gender, presence of thyroiditis,
nodule size, and border characteristics were compared
with definitive pathology. Ultrasonographic examina-
tions and FNACs were performed with a 10 MHz linear
transducer. The former technique was used to assess:
thyroid nodule dimension, features of thyroid paren-
chyma, nodule structure, echogenicity, edge regularity,
calcification pattern, and vascularization pattern. The
color Doppler pattern of the thyroid nodules was
evaluated and classified as follows: CDI (no vascula-
rization), CDII (peripheral vascular signal), CDIII (cen-
tral and peripheral vascular signal), and CDIV (diffuse
vascular signal).
FNACs were performed with ultrasound guidance,
using either a 22-gauge needle attached to a 10-mL dis-
posable plastic syringe or an aspirator. Samples were
stained with hematoxylin and eosin and evaluated by
our Pathology Department. Only patients presenting
Thy3 cytology were included in the study. Associations
between the ultrasonographic features of the nodules
and the histopathological results were evaluated to in-
vestigate whether nodule characteristics were predictive
for malignancy.
The study has been performed in accordance with the
Declaration of Helsinki. Ethical approval for our study
was obtained from institutional ethical committee of
Monserrato University Hospital, Cagliari. All patients
provided written informed consent for their involve-
ment in this study and for the storage and use of their
data.
Surgical complications were assessed over a follow-up
period that ranged between 6 and 54 months. Routine
pre- and post-operative fibrolaryngoscopy were performed
in all cases; vocal fold paresis was considered definitive
(paralysis) when still present 6 months after surgery.
Serum calcium (normal value = 2.09-2.54 mmol/L) and
iPTH (intact parathyroid hormone) levels (normal value =
1.06-6.89 pmol/L) were assessed on postoperative day 1.
An iPTH serum level < 1.06 pmol/L was used to deter-
mine postoperative hypoparathyroidism (considered defi-
nitive when present 6 months after surgery).
Statistical analysis
Data were analyzed using descriptive statistics: Pearson’s
chi-squared (exact) tests were used for categorical variables,
and independent Student’s t tests were used for quantitative
variables. Data were reported as the mean value ± standard
error of the mean (SEM). All calculations were performed
using the software package GraphPad Prism, Version 5.0
for Windows (GraphPad Software, San Diego, CA, USA).
Values were considered as statistically significant for
p ≤ 0.05.
Table 2 Ultrasonographic findings
Variables Benign pathology
(162/249)
Cancer
(87/249)
p
Echogenicity (%)
Hypoechoic 52/162 (32.1%) 54/87 (62.07%) < 0.001
Isoechoic + Hyperechoic 110/162 (67.9%) 33/87 (37.93%)
Microcalcifications (%)
Presence 34/162 (20.99%) 25/87 (28.74%) 0.22
Absence 128/162 (79.01%) 62/87 (71.26%)
CD Vascularization (%)
CDIII vascularization 88/162 (54.32%) 51/87 (58.62%) 0.60
CD I + II vascularization 74/162 (45.68%) 36/87 (41.38%)
Margin irregularity (%)
Presence of irregular
margins
13/162 (8.02%) 60/87 (68.97%) < 0.001
Absence 149/162 (91.98%) 27/87 (31.03%)
In boldface statistically significant data.
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Cyto-histological correlation
Hyperplastic nodular goiter was diagnosed in 107/249
cases (42.97%) by pathological examination, follicular ad-
enoma in 55/249 cases (22.1%), and malignancy in 87/249
patients (34.9%). In particular, papillary thyroid cancer
was found in 67/87 patients (77%), with 32/67 belonging
to the follicular variant subtype. Follicular thyroid cancer
was found in 18/87 cases (20.7%), whereas Hürthle cell
carcinoma lesions were found in 2 cases (2.3%).
Clinical data and histological diagnosis
Thyroiditis co-existed in 119/249 patients (47.79%); it was
associated with cancer in 40 patients (40/87; 45.98%) and
with benign pathology in 79/162 patients (48.77%: in
52 cases with a hyperplastic nodular goiter and in 27 with
a follicular adenoma). Cancer patients had a mean age
of 51.50 ± 14.95 years, were predominantly female (F/M =
4.11/1), and had a mean nodule size of 18.68 ± 11.45 mm
(range 6–47 mm; 8/87 malignant nodules were < 10 mm,
9.2%). Patients affected by benign disease had a mean age
of 52.98 ± 12.96 years, were predominantly female (F/M =
3.76/1), and had a mean nodule size of 17.90 ± 9.11 mm
(range 7–45 mm; 16/162 benign nodules were < 10 mm,
9.9%). None of these characteristics were statistically cor-
related with malignancy (see Table 1).
Ultrasonographic findings
Microcalcifications were present in 34/162 benign le-
sions (20.99%) and in 25/87 malignant lesions (28.74%).
Type 3 vascularization was present in 88/162 benign le-
sions (54.32%) and in 51/87 malignant lesions (58.62%);
neither association was statistically significant. 52/162
benign lesions (32.1%) and 54/87 malignant were hy-
poechoic (62.07%). Irregular margins were present in
13/162 (8.02%) benign lesions and 60/87 malignant
lesions (68.97%); these data were statistically significant
(see Table 2). Hypoechoic nodules associated with ir-
regular margins were present in 53/87 malignant lesions
(60.9%) and in 10/162 benign lesions (6.17%) (p < 0.001).
Surgical treatment and outcomes
TT was performed in all patients (249/249). Prophylactic
VI level lymphectomy was not performed in any patient;Table 1 Clinical and pathological data
Benign pathology
(162/249)
Cancer
(87/249)
p
Age 52.98 ± 12.96 51.50 ± 14.95 0.19
Female/male ratio 3.76 4.11 0.91
Tumor Size (mm.) 17.90 ± 9.11 (range 7–45) 18.68 ± 11.45
(range 6–47)
0.27
Consensual thyroiditis 48.77% 45.98% 0.77although this procedure is used in our Institute in cases
of macroscopic suspect nodes, considering the great
efficacy of radionuclide therapy and fewer associated
complications.
Recurrent laryngeal nerve transient paresis occurred in
2/249 patients (0.8%) and permanent hypoparathyroidism
occurred in 4/249 patients (1.6%). A cervical hematoma
was reported in 3/249 patients (1.2%); of these, 2 required
reintervention for bleeding control. Wound infection oc-
curred in just a single patient (0.4%).
Discussion
The increasing use of thyroid ultrasound scans has trig-
gered an epidemic of thyroid nodules [3]. Thyroid FNAC
is the most widely used diagnostic test in the manage-
ment of such nodules [11,16]. However, the usefulness
of FNAC is limited when dealing with follicular lesions
presenting cellular atypia of indeterminate significance
(Thy3), for which the distinction between benign and
malignant lesions is ambiguous [11].
Indeterminate follicular lesions comprise 10% to 30%
of cytopathological diagnoses [20]. This potentially
places a large economic burden on the health care sys-
tem due to the necessity for additional testing (FNAC
and/or imaging) and may heighten patient anxiety [20].
Overall rates of malignancy in nodules cytologically
diagnosed as FN have been reported to range between
16-52%, although the majority of studies report rates
between 20-30% [2-5,7,8,11,15,19].
In the present retrospective study of 249 patients pre-
senting indeterminate nodules (Thy3), 87 carcinomas
were identified (34.9%) – one of the highest malignancy
rates reported in the literature to date. This might be
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diagnosis of follicular neoplasm when follicular cells are
seen on aspirates. Another reason might be due to the fact
that our institution is a tertiary care referral center; thus,
patients presenting suspicious clinical or cytological fea-
tures suggestive of malignancy may have been preferen-
tially referred to our department, causing a bias in patient
selection.
Papillary thyroid cancer was identified as the most
common subtype of differentiated thyroid cancer diag-
nosed in atypical cells. This is consistent with other re-
ports [22].
Several authors have attempted to classify a subset of
nodules based on several clinical features and cytological
characteristics with the aim of predicting malignancy in
indeterminate nodules with greater accuracy [15]. The
clinical features previously explored and suggested to be
indicative of a malignant index nodule include: the male
sex, a young age (< 40 years), large nodule size (> 30–
40 mm), a high level of fixity to surrounding tissues,
hypoechogenicity, and the presence of microcalcifications
within nodules. Nevertheless, other authors have reported
the relative lack of accuracy of such clinical parameters in
predicting malignancy in indeterminate thyroid nodules
[3,15,16,19,20,22].
The male sex has been reported to represent a risk fac-
tor for malignancy [3,21], but this finding has not been
confirmed by others [8,14], nor in the present study. How-
ever, in the study performed by Sorrenti and colleagues
[4], males had an increased risk of malignancy when the
cytological diagnosis was Hürthle cell neoplasm.
The literature on the association between patient age
and thyroid cancer is inconsistent. Some authors report
no association between patient age at diagnosis and malig-
nancy [4,5,8], while others have identified a higher risk of
malignancy in younger patients with follicular neoplasms
[14,21]. In contrast, two recent studies reported that pa-
tients above 40 or 50 years of age presented an increased
incidence of malignancy [16,19]; while others simply re-
port a trend towards a higher prevalence of malignancy
with increasing age [8]. Other recent papers seem to pro-
vide an explanation to these contradicting results: by ana-
lyzing the distribution of cancer across different age
decades, the risk of malignancy was found to increase at
the two age extremes (< 30 yrs and > 60 yrs) [4,14,21]. In
the present study, the mean age of patients was slightly
lower in malignant lesions, but the data were not statisti-
cally significant; a similar result has also been reported in
other studies [4].
Several authors have asserted that bigger nodule sizes
are associated with malignancy [5], but others do not
confirm this [8,19,21]. Here, overall nodule size did not
result as a predictor of malignancy. Although the mean
size of malignant nodules was slightly larger than nonmalignant ones, the difference between the groups was
not statistically significance.
The relationship between Hashimoto’s thyroiditis and
thyroid cancer is a debatable matter [4]. Moreover, it was
recently reported that an increased rate of suspicious
cytology in thyroid nodules is associated with the presence
of positive thyroid auto-antibodies [23]. However, the
histological features of Hashimoto’s thyroiditis have rarely
been analyzed in studies evaluating the rate of malignancy
in indeterminate cytology. Two reports suggest that there
is no association between Hashimoto’s thyroiditis and ma-
lignancy [4,21], in line with the results of the present
study.
The sonographic features of thyroid nodules have con-
sistently failed to predict malignancy in FN with inde-
terminate cytology [13,14,22]. However, a hypoechoic
appearance, the presence of microcalcifications (defined
as < 2 mm hyperechoic spots), irregular or blurred mar-
gins, and intra-nodular vascularization are all taken as po-
tential markers of malignancy, especially when present in
combination [5,11,21]. The solid hypoechoic appearance
of thyroid nodules is considered by some to be the most
sensitive ultrasound parameter in predicting malignancy
[5,21]. In our study, the presence of microcalcifications
and type 3 vascularization were more likely to be associ-
ated with malignancy, but the correlation did not reach
statistical significance; while a hypoechoic appearance and
irregular margins were highly predictive of malignancy,
confirming the results of Cantisani [11].
Quantitative ultrasound elastography is more accurate
than conventional ultrasound in the diagnosis of thyroid
nodules and it is useful for the pre-surgical selection of
patients [5,8,11,24]. Malignant nodules have been con-
sistently reported to exhibit significantly greater stiffness
compared to benign lesions [5,11,24].
Cytological features, such as nuclear atypia, hypercellu-
larity, lack of colloid, and the hypercellularity to colloid
amount ratio, all increase the index of suspicion for malig-
nancy; however, their predictive value is also widely vari-
able [20]. Miller and colleagues [20] found that thyroid
cancer was most common in patients with atypical cells.
In the study by Dutta [15], only the absence of normal fol-
licular cells in FNAC was predictive of malignant lesions,
supporting the findings of previous reports [4,20]. In the
present study, no significant correlations between cyto-
logical features and malignancy were revealed, probably
because of the classification adopted.
At least 50 molecular markers have been analyzed in pa-
tients with thyroid nodules, and the use of immunocyto-
chemistry for detecting abnormally high levels of thyroid
peroxidase and galectin-3 in nodule FNAC seems to be
particularly promising for predicting malignancy [15].
Nodule aspirates positive for: galectin-3, BRAF point
mutations, the formation of PAX8-PPARγ1 chimeric
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ciated (even if to different extents) with thyroid cancer
risk [8,12,17,25-27]; thus, the combined analysis of mul-
tiple markers is likely to be of the greatest clinical use in
reducing the rate of unnecessary surgical procedures and
associated complications [8]. Nacamulli [24] combined
elastosonography with molecular testing for BRAF muta-
tions and found that it improved the preoperative identifi-
cation of thyroid malignancies; the author concluded that
this strategy holds great potential for reducing the number
of unnecessary surgical procedures. Alexander et al. [1]
reported the results of a large, prospective, multicenter
study validating a gene-expression classifier in patients
with indeterminate thyroid nodules: 78 of the 85 nodules
were identified as suspicious with a sensitivity of 92% and
a specificity of 52%; the authors suggest that a more con-
servative approach should be considered for most patients
with benign results from gene-expression classifier testing
[1]. The clinical utility of molecular testing was also evalu-
ated in the study by Nikiforov et al. [28], confirming a
high positive predictive value of BRAF, PAX8/PPARγ, and
RET/PTC mutations. However, in our opinion, although
these preliminary studies are certainly promising, the mo-
lecular testing of FNAC samples is not yet suitable for
standard practice.
No consensus has yet been reached in the literature re-
garding the management of patients with a diagnosis of
Thy3 thyroid nodules resulting from FNAC analysis. A very
important point of debate is the extent of surgery, implica-
ting issues such as level of clinical risk as well as the eco-
nomical costs associated with TT; various endocrinological
society guidelines recommend surgery without specifying
the extent of the treatment, yet no clinical investigation has
confirmed survival or morbidity benefits associated with
such a recommendation [8]. Several authors recommend
TT as the first-line surgical approach for multinodular goi-
ter, in particular for lesions greater than 1 cm in size, while
others recommend loboisthmectomy for a solitary nodule
[5,7,8,29]. The guidelines regarding simple lobectomy for
Thy3 solitary nodules take into account nodule dimension
and the availability of intraoperative examination of frozen
sections for the assessment of malignancy [8]. However, the
usefulness of intraoperative frozen section analysis is debat-
able, because the diagnosis of cancer depends on the de-
monstration of capsular and vascular invasion, which is
often not identified in frozen sections [4,7,8]. This has in-
deed been the case in our experience and was the reason
why frozen section histology was not performed. When a
lobectomy is performed, patients must be informed about
all risks including the possibility of a second operation
being required, thus also the patient’s own wishes must be
taken into account before commencing surgery [8].
In this study, the incidence of cancer was not negli-
gible (34.9%) and in a significant number of cases thecancer was also associated with thyroiditis (45.98%).
Hyperplastic nodular goiter was present in 42.97% of all
patients and thyroiditis in 47.79%. These high rates are ex-
plained by the fact that Sardinia is an endemic area for
thyroid diseases (hyperplastic goiter and Hashimoto’s thy-
roiditis in particular). Thus, considering the high incidence
of cancer, the high rates of associated thyroid pathologies
in Sardinia, and the current difficulties in preoperative and
intraoperative diagnosis, we suggest that TT should be the
treatment of choice for these patients. TT is a relatively
safe treatment with few complications when performed by
experienced endocrine surgeons; it also eliminates the risk
of reoperation (following a positive diagnosis for malig-
nancy after hemithyroidectomy, a relapse of goiter, or the
development of a tumor in the residual lobe) and the re-
lated high incidence of complications [30-36].
Conclusions
In conclusion, the risk of malignancy in cytologically inde-
terminate thyroid lesions was high in the present study
population. Moreover, in a significant number of cases,
Hashimoto’s thyroiditis and hyperplastic nodular goiter
were also associated with the cancer.
Clinical and cytological features were all found to be in-
accurate predictors of malignancy, and of the sonographic
features only hypoechoic appearance and irregular margins
were highly predictive of malignancy. Although various cor-
relations between malignancy and certain parameters have
been identified by other authors, the lack of any associa-
tions here may partly be explained by the relatively small
sample size.
Thus, due to the relatively high risk of malignancy in in-
determinate nodules observed here and the lack of highly
accurate predictors, we recommend surgery as the first-line
treatment of Thy3. Although, it is very difficult to
standardize the treatment of follicular lesions, we prefer TT
because it is the most suitable treatment for multiple le-
sions and when associated with hyperplastic nodular goiter
and thyroiditis. Furthermore the high incidence of malig-
nancy and the unreliability of intraoperative frozen section
examination support TT as the preferred treatment in the
large majority of cases. Nevertheless, hemithyroidectomy
may be preferential in selected cases, such as single
and small lesions, due to the low risk of associated
complications.
Further multicenter studies could contribute to the
standardization or modification of cytological classifications
by identifying patients at high and low risk, thereby refining
the recommended treatment profiles, in particular patient
suitability for hemi- or total thyroidectomy. The wider use
of immunocytochemical and genetic markers also holds
promise for improving nodule classifications and identifying
the patients with the greatest risk of developing thyroid
cancer.
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